Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.

Advertisements

Part 8. Rationale for SGLT2 Inhibitors Inhibit glucose reabsorption in the renal proximal tubule Resultant glucosuria leads to a decline in plasma glucose.

Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P

Part 1 of 4. Program Editors Ralph Anthony DeFronzo, MD Professor of Medicine and Chief of the Diabetes Division University of Texas Health Science Center.

Copyright © 2015 by the American Osteopathic Association.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Nat Clin Pract Endocrinol Metab 3: 279–289 doi: /ncpendmet0447

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1. Circadian pattern of gastric pH in healthy control subjects documented before (P1) Ramadan, on the 10th day (P2) and on the 24th day (P3) of.

Copyright © 2017 American Academy of Pediatrics.

A comparison of acute insulin responses to 5 g i. v

Nat. Rev. Cardiol. doi: /nrcardio

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.

Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Pathophysiology of hyperglycaemia in T2DM

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 6 Effects of adiponectin on podocyte function

Ghrelin—a new player in glucose homeostasis?

with undiagnosed diabetes mellitus by three diagnostic criteria

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.

Figure 1 Role of the kidney in glucose homeostasis

Figure 4 Effect of dapagliflozin on HbA1c and body weight

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Evidence for the incretin effect and

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 Glucose handling by the kidney

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Acute kidney injury and chronic kidney disease

filtration rate (GFR), and sodium (Na+) excretion

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Volume 26, Issue 1, Pages (July 2017)

Nat. Rev. Nephrol. doi: /nrneph

cardiovascular and renal systems

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Mikko Syvänne, MD, Marja-Riitta Taskinen, MD The Lancet

Nat. Rev. Endocrinol. doi: /nrendo

Glycemic Management in ESRD and Earlier Stages of CKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

James F. List, Jean M. Whaley Kidney International

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Sites of action of glucose-lowering agents

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Exercise enhances insulin sensitivity

Adiponectin hypothesis for insulin resistance, the metabolic syndrome, and atherosclerosis Takashi Kadowaki, et al. J. Clin. Invest :

The underlying physiological basis of the HOMA model.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.170 Figure 5 Effect of dapagliflozin on tissue sensitivity to insulin and β-cell function Figure 5 | Effect of dapagliflozin on tissue sensitivity to insulin and β-cell function. Treatment of patients with type 2 diabetes mellitus with dapagliflozin for 14 days led to a 25–30% improvement in muscle sensitivity to insulin (part a) and a nearly twofold increase in β-cell function (part b). The improvement in these two parameters resulted from the amelioration of glucotoxicity (that is, a reduction in plasma glucose concentration secondary to glucosuria) and contributed to improvements in overall glucose homeostasis. Part a modified with permission from Merovci, A. et al. J. Clin. Invest. 124, 509–514 (2014). Part b modified with permission from Merovci, A. et al. J. Clin. Endocrinol. Metab. 100, 1927–1932 (2015); permission conveyed through Copyright Clearance Center, Inc. Part a modified with permission from Merovci, A.et al. J. Clin. Invest. 124, 509–514 (2014). Part b modified with permission from Merovci, A. et al. J. Clin. Endocrinol. Metab. 100, 1927–1932 (2015); permission conveyed through Copyright Clearance Center, Inc. DeFronzo, R. A. et al. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.170